Drain of the brain: Low-affinity p75 neurotrophin receptor affords a molecular sink for clearance of cortical amyloid β by the cholinergic modulator system

Neurobiology of Aging

Volumn 34, Issue 11, 2013, Pages 2517-2524

  Ovsepian, Saak V ^a,b,c   Herms, Jochen ^a,b,c  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Germany 3 Munich Cluster for Systems Neurology   (Germany)

Author keywords

Alzheimer's disease; Amyloid ; Basal forebrain cholinergic neurons; Neurodegenerative disorders; P75 neurotrophin receptor

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; NEUROTROPHIN RECEPTOR P75;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; CHOLINERGIC NERVE CELL; ELECTROENCEPHALOGRAM; ENDOSOME; ENZYME ACTIVITY; ENZYME REGULATION; FOREBRAIN; HUMAN; LYSOSOME; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS;

ALZHEIMER'S DISEASE; AMYLOID Β; BASAL FOREBRAIN CHOLINERGIC NEURONS; NEURODEGENERATIVE DISORDERS; P75 NEUROTROPHIN RECEPTOR;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CEREBRAL CORTEX; CHOLINERGIC NEURONS; HUMANS; RECEPTOR, NERVE GROWTH FACTOR;

EID: 84881548898     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.05.005     Document Type: Article

References (124)

1. Aguzzi A., Barres B.A., Bennett M.L. Microglia: scapegoat, saboteur, or something else?. Science 2013, 339:156-161.
2. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschr. Psych. Psychisch-Gerichtliche Med. 1907, 64:146-148.
3. Arendash G.W., Millard W.J., Dunn A.J., Meyer E.M. Long-term neuropathological and neurochemical effects of nucleus basalis lesions in the rat. Science 1987, 238:952-956.
4. Arevalo M.A., Roldan P.M., Chacon P.J., Rodriguez-Tebar A. Amyloid beta serves as an NGF-like neurotrophic factor or acts as a NGF antagonist depending on its concentration. J.Neurochem. 2009, 111:1425-1433.
5. Bartus R.T., Flicker C., Dean R.L., Fisher S., Pontecorvo M., Figueiredo J. Behavioral and biochemical effects of nucleus basalis magnocellularis lesions: implications and possible relevance to understanding or treating Alzheimer's disease. Prog. Brain Res. 1986, 70:345-361.
6. Bero A.W., Yan P., Roh J.H., Cirrito J.R., Stewart F.R., Raichle M.E., Lee J.M., Holtzman D.M. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat. Neurosci. 2011, 14:750-756.
7. Blesch A. Neurotrophic factors in neurodegeneration. Brain Pathol. 2006, 16:295-303.
8. Blokland A. Acetylcholine: a neurotransmitter for learning and memory?. Brain Res. Brain Res. Rev. 1995, 21:285-300.
9. Bu G., Cam J., Zerbinatti C. LRP in amyloid-beta production and metabolism. Ann. N. Y. Acad. Sci. 2006, 1086:35-53.
10. Buckner R.L. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 2004, 44:195-208.
11. Buckner R.L., Andrews-Hanna J.R., Schacter D.L. The brain's default network: anatomy, function, and relevance to disease. Ann. N. Y. Acad. Sci. 2008, 1124:1-38.
12. Butowt R., von Bartheld C.S. Fates of neurotrophins after retrograde axonal transport: phosphorylation of p75NTR is a sorting signal for delayed degradation. J.Neurosci. 2009, 29:10715-10729.
13. Carpentier M., Robitaille Y., DesGroseillers L., Boileau G., Marcinkiewicz M. Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy. J.Neuropathol. Exp. Neurol. 2002, 61:849-856.
14. Cataldo A.M., Petanceska S., Terio N.B., Peterhoff C.M., Durham R., Mercken M., Mehta P.D., Buxbaum J., Haroutunian V., Nixon R.A. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol. Aging 2004, 25:1263-1272.
15. Chafekar S.M., Baas F., Scheper W. Oligomer-specific Abeta toxicity in cell models is mediated by selective uptake. Biochim. Biophys. Acta 2008, 1782:523-531.
16. Chow V.W., Mattson M.P., Wong P.C., Gleichmann M. An overview of APP processing enzymes and products. Neuromolecular Med. 2010, 12:1-12.
17. Cirrito J.R., Kang J.E., Lee J., Stewart F.R., Verges D.K., Silverio L.M., Bu G., Mennerick S., Holtzman D.M. Endocytosis is required for synaptic activity-dependent release of amyloid-beta invivo. Neuron 2008, 58:42-51.
18. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., Holtzman D.M. Synaptic activity regulates interstitial fluid amyloid-beta levels invivo. Neuron 2005, 48:913-922.
19. Costantini C., Weindruch R., Della Valle G., Puglielli L. ATrkA-to-p75NTR molecular switch activates amyloid beta-peptide generation during aging. Biochem. J. 2005, 391:59-67.
20. Counts S.E., Mufson E.J. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J.Neuropathol. Exp. Neurol. 2005, 64:263-272.
21. Crossgrove J.S., Li G.J., Zheng W. The choroid plexus removes beta-amyloid from brain cerebrospinal fluid. Exp. Biol. Med. (Maywood) 2005, 230:771-776.
22. Cupers P., Orlans I., Craessaerts K., Annaert W., De Strooper B. The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture. J.Neurochem. 2001, 78:1168-1178.
23. Davis K.L., Mohs R.C., Marin D., Purohit D.P., Perl D.P., Lantz M., Austin G., Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999, 281:1401-1406.
24. Dechant G., Barde Y.A. The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat. Neurosci. 2002, 5:1131-1136.
25. Deinhardt K., Reversi A., Berninghausen O., Hopkins C.R., Schiavo G. Neurotrophins redirect p75NTR from a clathrin-independent to a clathrin-dependent endocytic pathway coupled to axonal transport. Traffic 2007, 8:1736-1749.
26. Deinhardt K., Salinas S., Verastegui C., Watson R., Worth D., Hanrahan S., Bucci C., Schiavo G. Rab5 and Rab7 control endocytic sorting along the axonal retrograde transport pathway. Neuron 2006, 52:293-305.
27. Descarries L., Gisiger V., Steriade M. Diffuse transmission by acetylcholine in the CNS. Prog. Neurobiol. 1997, 53:603-625.
28. Edbauer D., Winkler E., Regula J.T., Pesold B., Steiner H., Haass C. Reconstitution of gamma-secretase activity. Nat. Cell Biol. 2003, 5:486-488.
29. El Khoury J., Toft M., Hickman S.E., Means T.K., Terada K., Geula C., Luster A.D. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 2007, 13:432-438.
30. Everitt B.J., Robbins T.W. Central cholinergic systems and cognition. Annu. Rev. Psychol. 1997, 48:649-684.
31. Fisher A. Cholinergic modulation of amyloid precursor protein processingwith emphasis on M1 muscarinic receptor: perspectives and challenges intreatment of Alzheimer's disease. J.Neurochem. 2012, 120(suppl 1):22-33.
32. Francis P.T., Palmer A.M., Sims N.R., Bowen D.M., Davison A.N., Esiri M.M., Neary D., Snowden J.S., Wilcock G.K. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment. N.Engl. J. Med. 1985, 313:7-11.
33. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J.Neurol. Neurosurg. Psychiatry 1999, 66:137-147.
34. Fuentealba R.A., Liu Q., Kanekiyo T., Zhang J., Bu G. Low density lipoprotein receptor-related protein 1 promotes anti-apoptotic signaling in neurons by activating Akt survival pathway. J.Biol. Chem. 2009, 284:34045-34053.
35. George-Hyslop P. Alzheimer's disease. Neurobiol. Dis. 2000, 7:546-548.
36. Geula C., Mesulam M.M., Saroff D.M., Wu C.K. Relationship between plaques, tangles, and loss of cortical cholinergic fibers in Alzheimer disease. J.Neuropathol. Exp. Neurol. 1998, 57:63-75.
37. Geula C., Nagykery N., Nicholas A., Wu C.K. Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J.Neuropathol. Exp. Neurol. 2008, 67:309-318.
38. Ginsberg S.D., Che S., Wuu J., Counts S.E., Mufson E.J. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J.Neurochem. 2006, 97:475-487.
39. Gouras G.K., Tampellini D., Takahashi R.H., Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol. 2010, 119:523-541.
40. Gouras G.K., Tsai J., Naslund J., Vincent B., Edgar M., Checler F., Greenfield J.P., Haroutunian V., Buxbaum J.D., Xu H., Greengard P., Relkin N.R. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 2000, 156:15-20.
41. Greicius M.D., Srivastava G., Reiss A.L., Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc. Natl. Acad. Sci. U.S.A 2004, 101:4637-4642.
42. Haass C., Kaether C., Thinakaran G., Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect. Med. 2012, 2:a006270.
43. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
44. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007, 10:1387-1394.
45. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
46. Hartz A.M., Miller D.S., Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol. Pharmacol. 2010, 77:715-723.
47. Hedden T., van Dijk K.R., Becker J.A., Mehta A., Sperling R.A., Johnson K.A., Buckner R.L. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J.Neurosci. 2009, 29:12686-12694.
48. Hersh L.B., Rodgers D.W. Neprilysin and amyloid beta peptide degradation. Curr. Alzheimer Res. 2008, 5:225-231.
49. Hook V., Kindy M., Hook G. Cysteine protease inhibitors effectively reduce invivo levels of brain beta-amyloid related to Alzheimer's disease. Biol. Chem. 2007, 388:247-252.
50. Hsieh H., Boehm J., Sato C., Iwatsubo T., Tomita T., Sisodia S., Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006, 52:831-843.
51. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., Gerard C., Hama E., Lee H.J., Saido T.C. Metabolic regulation of brain Abeta by neprilysin. Science 2001, 292:1550-1552.
52. Iwata N., Tsubuki S., Takaki Y., Watanabe K., Sekiguchi M., Hosoki E., Kawashima-Morishima M., Lee H.J., Hama E., Sekine-Aizawa Y., Saido T.C. Identificationof the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 2000, 6:143-150.
53. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13:45-53.
54. Kang D.E., Pietrzik C.U., Baum L., Chevallier N., Merriam D.E., Kounnas M.Z., Wagner S.L., Troncoso J.C., Kawas C.H., Katzman R., Koo E.H. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J.Clin. Invest. 2000, 106:1159-1166.
55. Kim J., Eltorai A.E., Jiang H., Liao F., Verghese P.B., Kim J., Stewart F.R., Basak J.M., Holtzman D.M. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis. J.Exp. Med. 2009, 209:2149-2156.
56. Kish S.J., Robitaille Y., el-Awar M., Deck J.H., Simmons J., Schut L., Chang L.J., DiStefano L., Freedman M. Non-Alzheimer-type pattern of brain cholineacetyltransferase reduction in dominantly inherited olivopontocerebellar atrophy. Ann. Neurol. 1989, 26:362-367.
57. Knauer M.F., Soreghan B., Burdick D., Kosmoski J., Glabe C.G. Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc. Natl. Acad. Sci. U.S.A 1992, 89:7437-7441.
58. Knowles J.K., Rajadas J., Nguyen T.V., Yang T., LeMieux M.C., Vander Griend L., Ishikawa C., Massa S.M., Wyss-Coray T., Longo F.M. The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy invitro and invivo. J.Neurosci. 2009, 29:10627-10637.
59. Koenigsknecht J., Landreth G. Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. J.Neurosci. 2004, 24:9838-9846.
60. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 8:499-509.
61. Lai A.Y., McLaurin J. Mechanisms of amyloid-beta peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins. Int. J. Alzheimers Dis. 2010, 2011:548380.
62. Lam F.C., Liu R., Lu P., Shapiro A.B., Renoir J.M., Sharom F.J., Reiner P.B. Beta-amyloid efflux mediated by p-glycoprotein. J.Neurochem. 2001, 76:1121-1128.
63. Laursen B., Mork A., Plath N., Kristiansen U., Bastlund J.F. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice. Behav. Brain Res. 2013, 240:146-152.
64. Li J., Kanekiyo T., Shinohara M., Zhang Y., LaDu M.J., Xu H., Bu G. Differential regulation of amyloid-beta endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J.Biol. Chem. 2012, 287:44593-44601.
65. Lichtenthaler S.F. Alpha-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential. J.Neurochem. 2011, 116:10-21.
66. Mackay E.A., Ehrhard A., Moniatte M., Guenet C., Tardif C., Tarnus C., Sorokine O., Heintzelmann B., Nay C., Remy J.M., Higaki J., Van Dorsselaer A., Wagner J., Danzin C., Mamont P. Apossible role for cathepsins D, E, and B in the processing of beta-amyloid precursor protein in Alzheimer's disease. Eur. J. Biochem. 1997, 244:414-425.
67. Mahadeo D., Kaplan L., Chao M.V., Hempstead B.L. High affinity nerve growth factor binding displays a faster rate of association than p140trk binding. Implications for multi-subunit polypeptide receptors. J.Biol. Chem. 1994, 269:6884-6891.
68. Marr R.A., Rockenstein E., Mukherjee A., Kindy M.S., Hersh L.B., Gage F.H., Verma I.M., Masliah E. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J.Neurosci. 2003, 23:1992-1996.
69. McKinney M., Jacksonville M.C. Brain cholinergic vulnerability: relevance to behavior and disease. Biochem. Pharmacol. 2005, 70:1115-1124.
70. Mesulam M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show?. Learn Mem. 2004, 11:43-49.
71. Mesulam M.M. The cholinergic innervation of the human cerebral cortex. Prog. Brain Res. 2004, 145:67-78.
72. Mesulam M.M., Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J.Comp. Neurol. 1988, 275:216-240.
73. Mori C., Spooner E.T., Wisniewsk K.E., Wisniewski T.M., Yamaguch H., Saido T.C., Tolan D.R., Selkoe D.J., Lemere C.A. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 2002, 9:88-102.
74. Mueller-Steiner S., Zhou Y., Arai H., Roberson E.D., Sun B., Chen J., Wang X., Yu G., Esposito L., Mucke L., Gan L. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 2006, 51:703-714.
75. Mufson E.J., Counts S.E., Fahnestock M., Ginsberg S.D. Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr. Alzheimer Res. 2007, 4:340-350.
76. Mufson E.J., Counts S.E., Perez S.E., Ginsberg S.D. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev. Neurother. 2008, 8:1703-1718.
77. Mullins C., Bonifacino J.S. The molecular machinery for lysosome biogenesis. Bioessays 2001, 23:333-343.
78. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., Buxbaum J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
79. Nitsch R.M., Slack B.E., Wurtman R.J., Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992, 258:304-307.
80. Nixon R.A. Autophagy, amyloidogenesis and Alzheimer disease. J.Cell Sci. 2007, 120:4081-4091.
81. Nixon R.A., Yang D.S. Autophagy and neuronal cell death in neurological disorders. Cold Spring Harb Perspect. Biol. 2012, 4.
82. Nixon R.A., Yang D.S., Lee J.H. Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy 2008, 4:590-599.
83. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43:321-332.
84. Ovsepian S.V., Dolly J.O., Zaborszky L. Intrinsic voltage dynamics govern the diversity of spontaneous firing profiles in basal forebrain noncholinergic neurons. J.Neurophysiol. 2012, 108:406-418.
85. Ovsepian, S.V., Antyborzec, I., O'Leary, V.B., Zaborszky, L., Herms, J., and Dolly, J.O., 2013. The neurotrophin receptor p75 mediates the uptake of the amyloid beta peptide, guiding it to lysosomes for degradation in basal forebrain cholinergic neurons. Brain Structure and Functions, in press.
86. Pasternak S.H., Bagshaw R.D., Guiral M., Zhang S., Ackerley C.A., Pak B.J., Callahan J.W., Mahuran D.J. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. J.Biol. Chem. 2003, 278:26687-26694.
87. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press. fourth ed.
88. Pelkmans L., Helenius A. Endocytosis via caveolae. Traffic 2002, 3:311-320.
89. Perini G., Della-Bianca V., Politi V., Della Valle G., Dal-Pra I., Rossi F., Armato U. Role of p75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines. J.Exp. Med. 2002, 195:907-918.
90. Perry E.K., Blessed G., Tomlinson B.E., Perry R.H., Crow T.J., Cross A.J., Dockray G.J., Dimaline R., Arregui A. Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes. Neurobiol. Aging 1981, 2:251-256.
91. Raichle M.E., MacLeod A.M., Snyder A.Z., Powers W.J., Gusnard D.A., Shulman G.L. Adefault mode of brain function. Proc. Natl. Acad. Sci. U.S.A 2001, 98:676-682.
92. Reinhard C., Hebert S.S., De Strooper B. The amyloid-beta precursor protein: integrating structure with biological function. EMBO J. 2005, 24:3996-4006.
93. Robitaille Y., Schut L., Kish S.J. Structural and immunocytochemical features of olivopontocerebellar atrophy caused by the spinocerebellar ataxia type 1 (SCA-1) mutation define a unique phenotype. Acta Neuropathol. 1995, 90:572-581.
94. Roher A.E., Kuo Y.M., Potter P.E., Emmerling M.R., Durham R.A., Walker D.G., Sue L.I., Honer W.G., Beach T.G. Cortical cholinergic denervation elicits vascular A beta deposition. Ann. N. Y. Acad. Sci. 2000, 903:366-373.
95. Runz H., Rietdorf J., Tomic I., de Bernard M., Beyreuther K., Pepperkok R., Hartmann T. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J.Neurosci. 2002, 22:1679-1689.
96. Russell M.R., Nickerson D.P., Odorizzi G. Molecular mechanisms of late endosome morphology, identity and sorting. Curr. Opin. Cell Biol. 2006, 18:422-428.
97. Saavedra L., Mohamed A., Ma V., Kar S., de Chaves E.P. Internalization of beta-amyloid peptide by primary neurons in the absence of apolipoprotein E. J.Biol .Chem. 2007, 282:35722-35732.
98. Salehi A., Ocampo M., Verhaagen J., Swaab D.F. P75 neurotrophin receptor in the nucleus basalis of meynert in relation to age, sex, and Alzheimer's disease. Exp. Neurol. 2000, 161:245-258.
99. Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimer's disease-interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem. Res. 2005, 30:895-908.
100. Schliebs R., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 2011, 221:555-563.
101. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., Zlokovic B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J.Clin. Invest. 2000, 106:1489-1499.
102. Smiley J.F., Morrell F., Mesulam M.M. Cholinergic synapses in human cerebral cortex: an ultrastructural study in serial sections. Exp. Neurol. 1997, 144:361-368.
103. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Nairn A.C., Salter M.W., Lombroso P.J., Gouras G.K., Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 2005, 8:1051-1058.
104. Sotthibundhu A., Sykes A.M., Fox B., Underwood C.K., Thangnipon W., Coulson E.J. Beta-amyloid(1-42) induces neuronal death through the p75 neurotrophin receptor. J.Neurosci. 2008, 28:3941-3946.
105. Sperling R.A., Laviolette P.S., O'Keefe K., O'Brien J., Rentz D.M., Pihlajamaki M., Marshall G., Hyman B.T., Selkoe D.J., Hedden T., Buckner R.L., Becker J.A., Johnson K.A. Amyloid deposition is associated with impaired defaultnetwork function in older persons without dementia. Neuron 2009, 63:178-188.
106. Suzuki K., Terry R.D. Fine structural localization of acid phosphatase in senile plaques in Alzheimer's presenile dementia. Acta Neuropathol. 1967, 8:276-284.
107. Takahashi R.H., Almeida C.G., Kearney P.F., Yu F., Lin M.T., Milner T.A., Gouras G.K. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J.Neurosci. 2004, 24:3592-3599.
108. Takahashi R.H., Milner T.A., Li F., Nam E.E., Edgar M.A., Yamaguchi H., Beal M.F., Xu H., Greengard P., Gouras G.K. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 2002, 161:1869-1879.
109. Takahashi R.H., Nam E.E., Edgar M., Gouras G.K. Alzheimer beta-amyloid peptides: normal and abnormal localization. Histol. Histopathol. 2002, 17:239-246.
110. Thal D.R., Capetillo-Zarate E., Del Tredici K., Braak H. The development of amyloid beta protein deposits in the aged brain. Sci. Aging Knowledge Environ. 2006, 2006:re1.
111. Thal D.R., Rub U., Orantes M., Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
112. Thinakaran G., Koo E.H. Amyloid precursor protein trafficking, processing, and function. J.Biol. Chem. 2008, 283:29615-29619.
113. Tuszynski M.H., Blesch A. Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease. Prog. Brain Res. 2004, 146:441-449.
114. van der Goot F.G., Gruenberg J. Intra-endosomal membrane traffic. Trends Cell Biol. 2006, 16:514-521.
115. Van Uden E., Mallory M., Veinbergs I., Alford M., Rockenstein E., Masliah E. Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J.Neurosci. 2002, 22:9298-9304.
116. Wang H.Y., Lee D.H., D'Andrea M.R., Peterson P.A., Shank R.P., Reitz A.B. Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J.Biol. Chem. 2000, 275:5626-5632.
117. Wang Y.J., Wang X., Lu J.J., Li Q.X., Gao C.Y., Liu X.H., Sun Y., Yang M., Lim Y., Evin G., Zhong J.H., Masters C., Zhou X.F. p75NTR regulates Abeta deposition by increasing Abeta production but inhibiting Abeta aggregation with its extracellular domain. J.Neurosci. 2011, 31:2292-2304.
118. Wang Y.J., Zhou H.D., Zhou X.F. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov. Today 2006, 11:931-938.
119. Weible M.W., Hendry I.A. What is the importance of multivesicular bodies in retrograde axonal transport invivo?. J.Neurobiol. 2004, 58:230-243.
120. Woolf N.J., Jacobs R.W., Butcher L.L. The pontomesencephalotegmental cholinergic system does not degenerate in Alzheimer's disease. Neurosci. Lett. 1989, 96:277-282.
121. Yaar M., Zhai S., Fine R.E., Eisenhauer P.B., Arble B.L., Stewart K.B., Gilchrest B.A. Amyloid beta binds trimers as well as monomers of the 75-kDa neurotrophin receptor and activates receptor signaling. J.Biol. Chem. 2002, 277:7720-7725.
122. Yaar M., Zhai S., Pilch P.F., Doyle S.M., Eisenhauer P.B., Fine R.E., Gilchrest B.A. Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J.Clin. Invest. 1997, 100:2333-2340.
123. Yan Z., Feng J. Alzheimer's disease: interactions between cholinergic functions and beta-amyloid. Curr. Alzheimer Res. 2004, 1:241-248.
124. Zarow C., Lyness S.A., Mortimer J.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 2003, 60:337-341.